Date Time
Share
Dana-Farber, Broad Institute and Count Me In receive $16 million grant to launch patient-partnered research initiatives
Funding from the National Cancer Institute will help optimize patient engagement in research while studying osteosarcoma and leiomyosarcoma
Dana-Farber Cancer Institute, The Broad Institute of MIT and Harvard, and Count Me In, a non-profit research initiative that conducts patient-partnered studies of cancer, have been awarded a new $16 million grant from the National Cancer Institute, to accelerate research in two rare forms of cancer. The funding will support research projects in leiomyosarcoma and osteosarcoma, two cancers which have seen few recent therapeutic advances, while simultaneously yielding new information about the best ways to engage with patients traditionally underrepresented in cancer research. The goal of these projects is to accelerate discoveries that can drive new insights into the genomic roots of rare cancer, discover mec
New NCCN Guidelines Analyze Evidence for Cancer Type Found Almost Exclusively in Children
USA - English
Share this article
Share this article
National Comprehensive Cancer Network publishes first-ever complete medical guidelines for a pediatric solid tumor, so children everywhere receive the best care based on the latest research.
NCCN Guidelines for Wilms Tumor shares information for earlier, safer diagnosis and treatment in effort to reduce disparities; doctors warn of late diagnosis as a possible impact from the COVID-19 pandemic.
PLYMOUTH MEETING, Pa., Feb. 17, 2021 /PRNewswire/ The National Comprehensive Cancer Network
®) today published its first-ever treatment guidelines for children with a solid tumor cancer type in the United States. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines
Share this article
Share this article
IRVING, Texas, Feb. 16, 2021 /PRNewswire/ Caris Life Sciences®, a leading innovator in molecular science and artificial intelligence focused on fulfilling the promise of precision medicine, announced today that the Dana-Farber Cancer Institute (Dana-Farber) has joined Caris Precision Oncology Alliance™ (The Alliance/POA). The Alliance is a collaborative network of leading cancer centers that work together to advance comprehensive cancer profiling and establish standards for molecular testing in oncology through research focused on predictive and prognostic markers that improve the clinical outcomes of patients with cancer. At Dana-Farber, it will operate out of the Lank Center for Genitourinary Oncology.
After Sofia learned she had cancer, her sister stepped in when she needed it most. Author: Liza Lucas Updated: 8:45 AM EST January 28, 2021
ATLANTA From shared laughs to shared adventures, Sofia and Bella Irlando have grown up together. The sisters side by side in the good times, and the hard ones, too.
Such bonds of sisterhood were put to the test after Sofia received the news she had acute myeloid leukemia, a cancer of the blood and bone marrow. It was obviously very scary, it was very stressful, Sofia told 11Alive of her diagnosis.
The news meant not only rounds of chemotherapy for Sofia, but the need for a bone marrow transplant.
email article
A widely used arthritis drug reduced the rate of acute graft-versus-host disease (GVHD) in both HLA-matched and -mismatched allogeneic stem-cell transplants, a randomized study showed.
The incidence of grade 3/4 acute GVHD after matched transplants decreased from 14.8% with standard prophylaxis to 6.8% with the addition of abatacept (Orencia). In a small group of patients who had 7/8-HLA-mismatched transplants, grade 3/4 acute GVHD at day 100 declined significantly from 30.2% with standard prophylaxis to 2.3% with add-on abatacept (
P 0.001).
Treatment with abatacept was not associated with increased rates of disease relapse or infection, investigators reported in the We found really striking results, particularly with those who were mismatched stem-cell transplants, in preventing acute GVHD, said Benjamin Watkins, MD, of Aflac Cancer and Blood Disorders Center and Emory University in Atlanta. This was a pretty rigorously run trial . and I think with thes